Next Article in Journal
Smart Delivery of Biomolecules Interfering with Peri-Implant Repair in Osteoporotic Rats
Previous Article in Journal
Density Gradient Centrifugation is an Effective Tool to Isolate Cancer Stem-Like Cells from Hypoxic and Normoxia Triple-Negative Breast Cancer Models
Previous Article in Special Issue
β-D-Glucose-Reduced Silver Nanoparticles Remodel the Tumor Microenvironment in a Murine Model of Triple-Negative Breast Cancer
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
IJMS
Volume 25
Issue 16
10.3390/ijms25168961
ijms-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Insights into E-Cadherin Impairment in CDH1-Unaltered Invasive Lobular Carcinoma: A Comprehensive Bioinformatic Study

by
Shiro Uchida
1,2,3,* and
Takashi Sugino
2
1
Division of Diagnostic Pathology, Kikuna Memorial Hospital, 4-4-27, Kikuna, Kohoku-ku, Yokohama 222-0011, Japan
2
Division of Pathology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan
3
Department of Human Pathology, Juntendo University School of Medicine, Tokyo 113-8421, Japan
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2024, 25(16), 8961; https://doi.org/10.3390/ijms25168961 (registering DOI)
Submission received: 25 June 2024 / Revised: 13 August 2024 / Accepted: 15 August 2024 / Published: 17 August 2024
(This article belongs to the Special Issue Breast Cancer, Metastatic Breast Cancer, Therapeutic Approaches, 2nd Edition)
Browse Figures
Versions Notes

Abstract

:
Invasive lobular carcinoma exhibits unique morphological features frequently associated with alterations in CDH1. Although some studies have identified abnormalities in adhesion factors other than E-cadherin, the molecular mechanisms underlying E-cadherin abnormalities in CDH1-unaltered invasive lobular carcinoma remain poorly understood. In this study, we investigated the molecular underpinnings of E-cadherin dysregulation in invasive lobular carcinoma in the absence of CDH1 gene alterations, using comprehensive bioinformatic analyses. We conducted a comparative study of CDH1-mutated and non-mutated invasive lobular carcinoma and evaluated the differences in mRNA levels, reverse-phase protein array, methylation, and miRNAs. We observed that invasive lobular carcinoma cases without CDH1 alterations exhibited a significantly higher incidence of the Claudin-low subtype (p < 0.01). The results of the reverse-phase protein array indicate no significant difference in E-cadherin expression between CDH1-mutated and non-mutated cases. Therefore, abnormalities in E-cadherin production also exist in CDH1 non-mutated invasive lobular carcinoma. Considering that there are no differences in mRNA levels and methylation status, post-translational modifications are the most plausible explanation for the same. Hence, future studies should focus on elucidating the mechanism underlying E-cadherin inactivation via post-translational modifications in CDH1 non-mutated invasive lobular carcinoma.

1. Introduction

Invasive lobular carcinoma (ILC) is one of the most frequently diagnosed specialized forms of breast cancer, accounting for approximately 5%–15% of all invasive breast cancer cases [1]. It is generally characterized by tumor cells that have lost their connectivity, and its unique histological appearance results from the inactivation of E-cadherin, encoded by the CDH1 gene [1]. CDH1 is located on the long arm of chromosome 16 (16q22.1) and is expressed in epithelial tissues. E-cadherin is a transmembrane glycoprotein that promotes calcium-dependent intercellular adhesion [2,3]. It bears extracellular, transmembrane, and intracellular domains, with the extracellular domain largely mediating intercellular adhesion and the intracellular domain being responsible for linking the protein to the cytoskeleton via α-, β-, and γ-catenin [4]. Previous studies have found abnormalities in the CDH1 coding sequence in 54% and 65% of ILC cases [5,6]. Abnormal CDH1 promoter methylation has also been frequently reported [7,8]. Nevertheless, the question of whether epigenetic gene silencing is responsible for the loss of CDH1 expression in ILC remains controversial [1,9]. In previous reports, immunohistochemical analysis showed that approximately 90% of ILC cases were E-cadherin-negative [10,11], i.e., a higher proportion compared to cases of CDH1 genetic abnormalities, suggesting that even in CDH1-unaltered ILC, E-cadherin production can be impaired. Other studies have shown that mutations in α-catenin (encoded by the CTNNA1 gene), which forms the cadherin–catenin complex that is important for intercellular adhesion, may underlie the lobular carcinoma phenotype even in the absence of CDH1 mutations and the presence of normal CDH1 expression [12]. Furthermore, a recent study examined the abnormal inactivation of other adhesion factors, such as CTNND1 and AXIN2, in ILC in the absence of CDH1 genetic alterations [13]. Overall, it is suggested that E-cadherin function can be impaired through various mechanisms in CDH1-unaltered ILC. However, studies focusing on CDH1-unaltered ILC are scarce, and several aspects regarding its clinicopathological (age, site, menopausal status, T factor, N factor, and tumor grade) and molecular characteristics (tumor mutational burden and co-mutated genes) remain unknown.
In the present study, we used bioinformatics tools, such as BioPortal, to analyze the clinicopathological features of ILC in the presence (CDH1-altered ILC) and absence (CDH1-unaltered ILC) of CDH1 alterations, utilizing datasets from The Cancer Genome Atlas (TCGA) and the Molecular Taxonomy of Breast Cancer International Consortium (METABRIC). Additionally, LinkedOmics was used to analyze the differences at the multi-omics level between CDH1-mutated and CDH1 non-mutated ILC.

2. Results

2.1. Clinicopathological Features, Intrinsic Subtype, and Tumor Mutational Burden of CDH1-Altered and -Unaltered ILC

We identified 110 samples of CDH1-altered ILC among the 201 ILC samples (110/201, 54.7%) in TCGA dataset and 91 samples among the 192 ILC samples (91/192, 47.4%) in the METABRIC dataset, yielding a total of 201 CDH1-altered ILC cases. CDH1 alterations included 13 missense (6.5%), 5 in-frame (2.5%), 23 splice-site (11.4%), 147 truncating (73.1%), 4 homozygous deletion-with-mutation (2.0%), 7 homozygous deletion-only (3.5%), and 2 structural variant (fusion) (1.0%) mutations (Table 1). All of the gene mutations were annotated using OncoKB [14]. Two structural variants (fusions), CDH1–NADK2 and CDH1–VPS50, were also identified. Annotations in OncoKB indicated that both were likely oncogenic, demonstrating a loss of CDH1 function.
No significant differences were observed in clinicopathological features between CDH1-altered and -unaltered ILC in terms of age, site of origin, menopausal status, T factor, N factor, and tumor grade (Table 2). No significant differences in the overall survival, disease-free status, or relapse-free status were identified between the groups either (Figure 1a–c).
Tumor mutational burden (TMB) was not significantly different between the CDH1-altered and -unaltered groups (p = 0.05); 84.1% of the CDH1-altered group had a low TMB and 15.9% had a high TMB, whereas 88.3% of the CDH1-unaltered group had a low TMB and 11.7% had a high TMB (Table 2). Among the intrinsic subtypes, a significant prevalence of the Claudin-low (CL) subtype was observed in CDH1-unaltered ILC in the METABRIC dataset. No significant difference between the two groups was found in the TCGA analysis (Table 3).

2.2. Genomic Landscape of Somatic Mutations and Comparison of Somatic Mutations and Amplification between CDH1-Altered and -Unaltered ILC

Oncoplots summarizing all gene names, the presence/absence of mutations, mutation type, mutation frequency, and amplification/deletion of ERBB2, ERBB3, and FGFR1 for each group within CDH1-altered and -unaltered ILC are shown in Figure 2. The results of detailed statistical analyses are summarized in Table S1. PIK3CA, RUNX1, and ERBB2 mutation frequencies were significantly lower in CDH1-unaltered ILC than in CDH1-altered ILC (p < 0.05). However, there were no significant differences in other gene mutations or in the amplification of ERBB2, ERBB3, or FGFR1.

2.3. Identification of Differences in CDH1 mRNA, Protein, Methylation, and miRNA (hsa-mir-676) Levels between CDH1-Mutant and Non-Mutant Groups Using LinkedOmics

LinkedOmics analysis revealed no significant differences in the levels of CDH1 mRNA, protein (E-cadherin), methylation, or hsa-mir-676 between CDH1-mutant and non-mutant ILC (Figure 3). Among the miRNAs, hsa-mir-676 was the most highly expressed in CDH1 non-mutant ILC; however, no significant differences were identified in RNA-seq, reverse-phase protein array (RPPA), methylation, or miRNA analyses. In summary, there were no significant changes in CDH1 mRNA, protein, or methylation levels in the presence or absence of CDH1 mutations, and no miRNAs were significantly upregulated in CDH1 non-mutant ILC.

2.4. Gene Set Enrichment Analysis (GSEA) of Gene Ontology Annotations

Via GSEA, we identified several key Gene Ontology (GO) terms, with protein localization in the endoplasmic reticulum showing significant enrichment. Although the false discovery rates (FDRs) exceeded 0.05, chaperone-mediated protein complex assembly and protein folding were recognized as important biological processes (Figure 4A). Furthermore, the structural constitution of ribosomes and tRNA binding were determined to be crucial for molecular function (Figure 4B). It is important to note that the chaperone complex remains an essential and major cellular process (Figure 4C). In summary, GSEA revealed significant differences in various functions related to protein synthesis processes between CDH1-mutated and CDH1 non-mutated ILC.

3. Discussion

We used datasets from TCGA and the METABRIC to examine CDH1 gene alterations in ILC. We classified ILC into CDH1-altered and -unaltered groups and compared their clinicopathological characteristics and associated genetic mutations. We found that CDH1 alterations were present in 51.1% (201/393) of ILC cases, with truncating mutations comprising 73.1% (134/201) of these alterations, making them the most prevalent mutation type observed. The observed CDH1-alteration frequency and the high number of truncating mutations were generally consistent with previous reports [5,6,9]. Two fusion genes, CDH1–NADK2 and CDH1–VPS50, were identified in this study. Both were annotated as likely oncogenic by OncoKB, suggesting a loss of CDH1 function. When comparing CDH1-altered and -unaltered ILC, PIK3CA, RUNX1, and ERBB2 mutation frequencies were significantly higher in CDH1-altered ILC. This could be attributed to the fact that PIK3CA and RUNX1 mutations are commonly observed in luminal-type breast cancer; in the intrinsic subtype, CDH1-altered ILC exhibited a higher proportion of luminal-type cases. This may explain the high occurrence of these genetic mutations [15]. ERBB2 mutations are significantly enriched in CDH1 mutations and are considered common in CDH1-altered ILC [16,17,18].
In the METABRIC dataset, CDH1-unaltered ILC had a higher proportion of CL intrinsic subtype cases compared to CDH1-altered ILC. The CL type is characterized by low expression of tight junction proteins and adhesion proteins (Claudins 3, 4, and 7 and E-cadherin) and high expression of mesenchymal, extracellular matrix, and epithelial–mesenchymal transition (EMT) proteins, such as vimentin, SNAI 1/2, Twist 1/2, and ZEB 1/2 [19]. Previous reports have shown that metaplastic carcinoma and invasive ductal carcinoma are common in CL, but ILC has also been reported to occur in approximately 4% of cases [19,20]. Generally, EMT-related genes such as TWIST and SNAIL are known to suppress E-cadherin expression. However, although EMT typically occurs in the final stages of tumor progression, in ILC, the E-cadherin level decreases from the early stages of development. It has been reported that the low E-cadherin level in ILC is not associated with EMT [5].
With respect to the prognostic value of reduced E-cadherin levels in breast cancer, previous studies found that these promoted tumor invasion and metastasis [3,21]; as a result, overall survival and disease-free survival duration were significantly shorter and correlated with tumor histological grade, TNM stage, tumor size, and the presence of lymph node metastasis [22,23,24]. Although we anticipated that the presence or absence of CDH1 mutations would result in differences at the protein levels, interestingly, LinkedOmics analysis revealed no significant differences in E-cadherin levels when comparing CDH1-mutated with non-mutated ILC. These findings indicate that in CDH1 non-mutated ILC, although there are no mutations in the CDH1 gene, E-cadherin expression is reduced, suggesting that abnormalities in E-cadherin protein synthesis may occur even in CDH1 non-mutated ILC.
The previous literature has identified five mechanisms of E-cadherin inactivation in breast cancer: (i) mutation, (ii) a loss of heterozygosity, (iii) promoter methylation, (iv) transcriptional repression, and (v) post-translational modifications (such as aberrant glycosylation) [25]. The existence of N-terminal-deficient impaired E-cadherins has recently been proposed. Although the mechanism underlying the production of N-terminal-deficient E-cadherins is still unknown, post-translational modifications are thought to be involved [26]. The mechanism underlying E-cadherin inactivation in CDH1 non-mutated ILC is unlikely to involve promoter methylation or transcriptional repression, as LinkedOmics analysis revealed no differences in mRNA or methylation levels. Additionally, no miRNAs inhibiting CDH1 expression were identified. In contrast, the mechanisms of E-cadherin inactivation, such as post-translational modifications (e.g., aberrant glycosylation) and N-terminal-deficient E-cadherin production, are independent of genetic alterations, promoter methylation, and transcriptional repression. Therefore, these mechanisms could be plausible contributors to E-cadherin dysregulation in CDH1 non-mutated ILC. In addition, GSEA detected GO terms associated with protein production (i.e., protein localization to the endoplasmic reticulum, the structural constitution of ribosomes, ribosome activity, tRNA binding, and the chaperone complex), which supports the hypothesis of abnormalities in protein production in CDH1 non-mutated ILC. Post-translational modifications such as O- and N-glycosylation are reportedly important for E-cadherin production [27,28] as well as its folding, transport, and stability at the membrane [29,30,31,32]. E-cadherin deglycosylation at Asn-633 has been shown to result in its degradation via the endoplasmic reticulum-associated degradation mechanism in the absence of correct folding [31]. Such post-translational modifications have been suggested for E-cadherin in CDH1 non-mutated ILC. As a result of these abnormalities, GO terms related to protein production may have been detected. Regarding N-terminal-deficient E-cadherin production, it is currently considered that incomplete E-cadherin lacking the N-terminus is produced via post-translational modifications involving enzymatic cleavage by matrix metalloproteinases (MMPs), a disintegrin and metalloproteinases (ADAMs), and neutrophil elastase [26].
The findings of this study suggest that post-translational modifications (such as aberrant glycosylation) and N-terminal-deficient E-cadherin production play a significant role in the pathogenesis of CDH1-unaltered ILC. Currently, the mechanisms underlying E-cadherin inactivation via post-translational modifications have not been elucidated, necessitating further research in this area. This study presented an important limitation. It exclusively used bioinformatic approaches and considered abnormal E-cadherin production through impaired protein production processes and post-translational modifications as a possible molecular mechanism of CDH1-unaltered ILC, but did not validate the findings using human tissues or cultured cells from breast lobular carcinoma. In the future, it will be necessary to experimentally investigate whether glycosylation abnormalities actually occur in ILC cell lines and human specimens of ILC and whether proteolytic enzymes such as MMPs and ADAMs are indeed involved in the production of N-terminal-deficient E-cadherin.

4. Materials and Methods

4.1. Data Collection of CDH1-Altered and -Unaltered ILC

Genomic and clinical data were collected from breast invasive lobular carcinoma samples using cBioPortal. Specifically, data from TCGA PanCancer Atlas dataset (Breast Invasive Carcinoma) [33] and the METABRIC dataset (breast cancer) [34,35] (n = 201 and n = 192, respectively) were obtained. Next, we categorized the cases into CDH1-altered and -unaltered ILC. CDH1 alterations were considered to include structural variants (fusions), copy number alterations (homozygous deletions), and mutations. For TCGA and the METABRIC, CDH1-altered (n = 110 and n = 91) and -unaltered (n = 91 and n = 101) ILC cases were identified, respectively, resulting in a total of 201 CDH1-altered and 192 CDH1-unaltered ILC cases. A detailed case selection flowchart is shown in Figure 5.

4.2. Comparison of Clinicopathological Features and Molecular Subtypes between CDH1-Altered and -Unaltered ILC

For ILC samples, the age (mean), sex distribution, site of onset, T factor, N factor, tumor grade, and molecular subtype were obtained from cBioPortal (New York, NY, USA). Where information was not available, it was designated as “N/A” and excluded from percentage calculations. However, no tumor grade information was available for TCGA dataset. In addition, the overall survival, disease-free status, and relapse-free status were analyzed. Overall survival analysis was performed by integrating data from TCGA and the METABRIC, with data from TCGA being used only for disease-free status and those from the METABRIC only for relapse-free status. In TCGA dataset, intrinsic subtypes were determined using the PAM50 multi-gene assay and classified into five categories: luminal A, luminal B, Her-2 enriched, basal-like, and normal-like. Conversely, in the METABRIC dataset, classification using the PAM50 assay was expanded to include the CL subtype, which allowed for categorization into six distinct types.

4.3. TMB Estimation

TMB is a measure of the total number of mutations per megabase (Mb) of tumor tissue. It can also be interpreted as the mutation density in tumor genes, defined as the average number of mutations in the tumor genome, including the total number of coding sequence errors, base substitutions, insertions, or deletions. This information was obtained from two datasets. The samples were classified as TMB-high if they had ≥10 mutations per Mb (mut/Mb) and TMB-low if they had <10 mut/Mb, as described previously [36]. We compared the TMB for each cancer type between the CDH1-altered and -unaltered ILC groups, as well as the TMB low-to-high ratio.

4.4. CDH1 Alteration Analysis and Comparison of Mutation and Amplification Frequency of CDH1-Related Genes between CDH1-Altered and -Unaltered ILC

We used cBioPortal to investigate ILC and subsequent genetic alterations. Genes closely related to ILC were selected from previous studies [9,37], and the frequency of each gene mutation was compared between CDH1-altered and -unaltered ILC: PIK3CA, FOXA1, TBX3, GATA3, RUNX1, PTEN, MAP3K1, ERBB2, ERBB3, FGFR1, NF1, AKT1, TP53, ARID1A, and KMT2C. We also investigated ERBB2, ERBB3, and FGFR1 amplification. The detected genetic alterations were visualized using Oncoprinter on the cBioPortal.

4.5. LinkedOmics Analysis

LinkedOmics (http://www.linkedomics.org/login.php) on 1 April 2024, a public online analysis tool, contains cancer-associated multidimensional datasets derived from all 32 TCGA types [38]. First, we selected the “TCGA_BRCA” cancer cohort and the following parameters: data type, “mutation”; attribute, “CDH1”; sample dataset, “infiltrating lobular carcinoma”; target dataset, “RNA-seq”, “reverse phase protein array (RPPA)”, “methylation”, and “miRNA-seq”. The statistical method used was the Wilcoxon test. CDH1 mRNA, protein, and methylation levels were compared between the CDH1-mutant and non-mutant groups. For miRNAs, hsa-mir-676 was most highly expressed in the CDH1 non-mutant group; therefore, its expression was compared between the two groups. Moreover, enrichment analysis using GO annotations, GO (biological process), GO analysis (cellular component), and GO (molecular function) was performed using the Linkinterpreter for RNA-seq data [select tool: GSEA; rank criteria: p-value; simulations: 500 times]. Differences were considered significant when both the p-value and FDR were <0.05.

4.6. Statistical Analysis

The clinicopathological and intrinsic subtype differences between CDH1-altered and -unaltered ILC were analyzed using the chi-squared test. The TMB between CDH1-altered and -unaltered samples was analyzed using the Mann–Whitney U test. Chi-squared tests were performed to determine the frequency of ILC-related mutations. Statistical significance was set at p < 0.05 and FDR < 0.05. All statistical analyses were performed using EZR software (version 1.55) [39].

5. Conclusions

In summary, CDH1-unaltered ILC was more frequently associated with the CL subtype, resulting in a different subtype distribution compared to CDH1-altered ILC, which led to significant differences in associated gene mutations. Interestingly, the LinkedOmics results revealed no significant difference in E-cadherin protein levels between CDH1-mutated and CDH1 non-mutated ILC, demonstrating that E-cadherin expression is impaired in CDH1 non-mutated ILC. Considering that there were no differences in mRNA and methylation levels, post-translational modifications (such as aberrant glycosylation) and N-terminal-deficient E-cadherin production are the most plausible explanations for E-cadherin inactivation in CDH1-unaltered ILC, and this subject warrants further investigation.

Supplementary Materials

The following supporting information can be downloaded at https://www.mdpi.com/article/10.3390/ijms25168961/s1.

Author Contributions

Conceptualization, S.U. and T.S.; methodology, S.U.; validation, S.U. and T.S.; formal analysis, S.U.; investigation, S.U.; data curation, S.U.; writing—original draft preparation, S.U.; writing—review and editing, T.S.; visualization, S.U. All authors have read and agreed to the published version of the manuscript.

Funding

This study received no external funding.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

The datasets generated and/or analyzed in this study are available from the corresponding author on reasonable request.

Conflicts of Interest

The authors declare no conflicts of interest.

References

  1. World Health Organization Classification of Tumours Editorial Board. Breast Tumors, 5th ed.; International Agency for Research on Cancer (International Arctic Research Center): Lyon, France, 2019. [Google Scholar]
  2. Berx, G.; Cleton-Jansen, A.M.; Nollet, F.; de Leeuw, W.J.; van de Vijver, M.; Cornelisse, C.; van Roy, F. E-cadherin is a tumour/invasion suppressor gene mutated in human lobular breast cancers. EMBO J. 1995, 14, 6107–6115. [Google Scholar] [CrossRef] [PubMed]
  3. Takeichi, M. Cadherin cell adhesion receptors as a morphogenetic regulator. Science 1991, 251, 1451–1455. [Google Scholar] [CrossRef]
  4. van Roy, F.; Berx, G. The cell-cell adhesion molecule E-cadherin. Cell Mol. Life Sci. 2008, 65, 3756–3788. [Google Scholar] [CrossRef] [PubMed]
  5. McCart Reed, A.E.; Kutasovic, J.R.; Lakhani, S.R.; Simpson, P.T. Invasive lobular carcinoma of the breast: Morphology, biomarkers and ’omics. Breast Cancer Res. 2015, 17, 12. [Google Scholar] [CrossRef] [PubMed]
  6. Desmedt, C.; Zoppoli, G.; Gundem, G.; Pruneri, G.; Larsimont, D.; Fornili, M.; Fumagalli, D.; Brown, D.; Rothé, F.; Vincent, D.; et al. Genomic characterization of primary invasive lobular breast cancer. J. Clin. Oncol. 2016, 34, 1872–1881. [Google Scholar] [CrossRef]
  7. Zou, D.; Yoon, H.S.; Perez, D.; Weeks, R.J.; Guilford, P.; Humar, B. Epigenetic silencing in non-neoplastic epithelia identifies E-cadherin (CDH1) as a target for chemoprevention of lobular neoplasia. J. Pathol. 2009, 218, 265–272. [Google Scholar] [CrossRef]
  8. Liu, J.; Sun, X.; Qin, S.; Wang, H.; Du, N.; Li, Y.; Pang, Y.; Wang, C.; Xu, C.; Ren, H. CDH1 promoter methylation correlates with decreased gene expression and poor prognosis in patients with breast cancer. Oncol. Lett. 2016, 11, 2635–2643. [Google Scholar] [CrossRef]
  9. Ciriello, G.; Gatza, M.L.; Beck, A.H.; Wilkerson, M.D.; Rhie, S.K.; Pastore, A.; Zhang, H.; McLellan, M.; Yau, C.; Kandoth, C.; et al. Comprehensive molecular portraits of invasive lobular breast cancer. Cell 2015, 163, 506–519. [Google Scholar] [CrossRef] [PubMed]
  10. Canas-Marques, R.; Schnitt, S.J. E-cadherin immunohistochemistry in breast pathology: Uses and pitfalls. Histopathology 2016, 68, 57–69. [Google Scholar] [CrossRef] [PubMed]
  11. Grabenstetter, A.; Mohanty, A.S.; Rana, S.; Zehir, A.; Brannon, A.R.; D’Alfonso, T.M.; DeLair, D.F.; Tan, L.K.; Ross, D.S. E-cadherin immunohistochemical expression in invasive lobular carcinoma of the breast: Correlation with morphology and CDH1 somatic alterations. Hum. Pathol. 2020, 102, 44–53. [Google Scholar] [CrossRef]
  12. de Groot, J.S.; Ratze, M.A.; van Amersfoort, M.; Eisemann, T.; Vlug, E.J.; Niklaas, M.T.; Chin, S.F.; Caldas, C.; van Diest, P.J.; Jonkers, J.; et al. αE-catenin is a candidate tumor suppressor for the development of E-cadherin-expressing lobular-type breast cancer. J. Pathol. 2018, 245, 456–467. [Google Scholar] [CrossRef] [PubMed]
  13. Dopeso, H.; Gazzo, A.M.; Derakhshan, F.; Brown, D.N.; Selenica, P.; Jalali, S.; Da Cruz Paula, A.; Marra, A.; da Silva, E.M.; Basili, T.; et al. Genomic and epigenomic basis of breast invasive lobular carcinomas lacking CDH1 genetic alterations. NPJ Precis. Oncol. 2024, 8, 33. [Google Scholar] [CrossRef]
  14. Chakravarty, D.; Gao, J.; Phillips, S.M.; Kundra, R.; Zhang, H.; Wang, J.; Rudolph, J.E.; Yaeger, R.; Soumerai, T.; Nissan, M.H.; et al. OncoKB: A precision oncology knowledge base. JCO Precis. Oncol. 2017, 2017, PO.17.00011. [Google Scholar] [CrossRef]
  15. Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature 2012, 490, 61–70. [Google Scholar] [CrossRef] [PubMed]
  16. Ross, J.S.; Wang, K.; Sheehan, C.E.; Boguniewicz, A.B.; Otto, G.; Downing, S.R.; Sun, J.; He, J.; Curran, J.A.; Ali, S.; et al. Relapsed classic E-cadherin (CDH1)-mutated invasive lobular breast cancer shows a high frequency of HER2 (ERBB2) gene mutations. Clin. Cancer Res. 2013, 19, 2668–2676. [Google Scholar] [CrossRef] [PubMed]
  17. Kurozumi, S.; Alsaleem, M.; Monteiro, C.J.; Bhardwaj, K.; Joosten, S.E.P.; Fujii, T.; Shirabe, K.; Green, A.R.; Ellis, I.O.; Rakha, E.A.; et al. Targetable ERBB2 mutation status is an independent marker of adverse prognosis in estrogen receptor positive, ERBB2 non-amplified primary lobular breast carcinoma: A retrospective in silico analysis of public datasets. Breast Cancer Res. 2020, 22, 85. [Google Scholar] [CrossRef] [PubMed]
  18. Uchida, S.; Kojima, T.; Sugino, T. Clinicopathological features, tumor mutational burden, and tumour-infiltrating lymphocyte interplay in ERBB2-mutated breast cancer: In silico analysis. Pathol. Oncol. Res. 2021, 27, 633243. [Google Scholar] [CrossRef] [PubMed]
  19. Pan, C.; Xu, A.; Ma, X.; Yao, Y.; Zhao, Y.; Wang, C.; Chen, C. Research progress of claudin-low breast cancer. Front. Oncol. 2023, 13, 1226118. [Google Scholar] [CrossRef]
  20. Sabatier, R.; Finetti, P.; Guille, A.; Adelaide, J.; Chaffanet, M.; Viens, P.; Birnbaum, D.; Bertucci, F. Claudin-low breast cancers: Clinical, pathological, molecular and prognostic characterization. Mol. Cancer. 2014, 13, 228. [Google Scholar] [CrossRef] [PubMed]
  21. Deeb, G.; Wang, J.; Ramnath, N.; Slocum, H.K.; Wiseman, S.; Beck, A.; Tan, D. Altered E-cadherin and epidermal growth factor receptor expressions are associated with patient survival in lung cancer: A study utilizing high-density tissue microarray and immunohistochemistry. Mod. Pathol. 2004, 17, 430–439. [Google Scholar] [CrossRef]
  22. Hunt, N.C.; Douglas-Jones, A.G.; Jasani, B.; Morgan, J.M.; Pignatelli, M. Loss of E-cadherin expression associated with lymph node metastases in small breast carcinomas. Virchows Arch. 1997, 430, 285–289. [Google Scholar] [CrossRef]
  23. Li, Z.; Yin, S.; Zhang, L.; Liu, W.; Chen, B. Prognostic value of reduced E-cadherin expression in breast cancer: A meta-analysis. Oncotarget. 2017, 8, 16445–16455. [Google Scholar] [CrossRef] [PubMed]
  24. Yang, L.; Wang, X.W.; Zhu, L.P.; Wang, H.L.; Wang, B.; Zhao, Q.; Wang, X.Y. Significance and prognosis of epithelial-cadherin expression in invasive breast carcinoma. Oncol. Lett. 2018, 16, 1659–1665. [Google Scholar] [CrossRef] [PubMed]
  25. Corso, G.; Figueiredo, J.; De Angelis, S.P.; Corso, F.; Girardi, A.; Pereira, J.; Seruca, R.; Bonanni, B.; Carneiro, P.; Pravettoni, G.; et al. E-cadherin deregulation in breast cancer. J. Cell Mol. Med. 2020, 25, 5930–5936. [Google Scholar] [CrossRef] [PubMed]
  26. Yasui, H.; Kawata, T.; Muramatsu, K.; Kakuda, Y.; Oishi, T.; Norose, T.; Notsu, A.; Nishimura, S.; Fukuoka, J.; Sugino, T. Expression of N-terminal-deficient E-cadherin protein in invasive lobular carcinoma of the breast. Am. J. Surg. Pathol. 2022, 46, 383–391. [Google Scholar] [CrossRef]
  27. Pinho, S.S.; Reis, C.A.; Paredes, J.; Magalhães, A.M.; Ferreira, A.C.; Figueiredo, J.; Xiaogang, W.; Carneiro, F.; Gärtner, F.; Seruca, R. The role of N-acetylglucosaminyltransferase III and V in the post-transcriptional modifications of E-cadherin. Hum. Mol. Genet. 2009, 18, 2599–2608. [Google Scholar] [CrossRef]
  28. Pinho, S.S.; Seruca, R.; Gärtner, F.; Yamaguchi, Y.; Gu, J.; Taniguchi, N.; Reis, C.A. Modulation of E-cadherin function and dysfunction by N-glycosylation. Cell Mol. Life Sci. 2011, 68, 1011–1020. [Google Scholar] [CrossRef]
  29. Pinho, S.S.; Carvalho, S.; Marcos-Pinto, R.; Magalhães, A.; Oliveira, C.; Gu, J.; Dinis-Ribeiro, M.; Carneiro, F.; Seruca, R.; Reis, C.A. Gastric cancer: Adding glycosylation to the equation. Trends Mol. Med. 2013, 19, 664–676. [Google Scholar] [CrossRef] [PubMed]
  30. Pinho, S.S.; Figueiredo, J.; Cabral, J.; Carvalho, S.; Dourado, J.; Magalhães, A.; Gärtner, F.; Mendonfa, A.M.; Isaji, T.; Gu, J.; et al. E-cadherin and adherens-junctions stability in gastric carcinoma: Functional implications of glycosyltransferases involving N-glycan branching biosynthesis, N-acetylglucosaminyltransferases III and V. Biochim. Biophys. Acta 2013, 1830, 2690–2700. [Google Scholar] [CrossRef] [PubMed]
  31. Zhou, F.; Su, J.; Fu, L.; Yang, Y.; Zhang, L.; Wang, L.; Zhao, H.; Zhang, D.; Li, Z.; Zha, X. Unglycosylation at Asn-633 made extracellular domain of E-cadherin folded incorrectly and arrested in endoplasmic reticulum, then sequentially degraded by ERAD. Glycoconj. J. 2008, 25, 727–740. [Google Scholar] [CrossRef] [PubMed]
  32. Liwosz, A.; Lei, T.; Kukuruzinska, M.A. N-glycosylation affects the molecular organization and stability of E-cadherin junctions. J. Biol. Chem. 2006, 281, 23138–23149. [Google Scholar] [CrossRef] [PubMed]
  33. Hoadley, K.A.; Yau, C.; Hinoue, T.; Wolf, D.M.; Lazar, A.J.; Drill, E.; Shen, R.; Taylor, A.M.; Cherniack, A.D.; Thorsson, V.; et al. Cell-of-origin patterns dominate the molecular classification of 10,000 tumors from 33 types of cancer. Cell 2018, 173, 291–304. [Google Scholar] [CrossRef] [PubMed]
  34. Curtis, C.; Shah, S.P.; Chin, S.F.; Turashvili, G.; Rueda, O.M.; Dunning, M.J.; Speed, D.; Lynch, A.G.; Samarajiwa, S.; Yuan, Y.; et al. The genomic and transcriptomic architecture of 2000 breast tumours reveals novel subgroups. Nature 2012, 486, 346–352. [Google Scholar] [CrossRef] [PubMed]
  35. Pereira, B.; Chin, S.F.; Rueda, O.M.; Vollan, H.K.M.; Provenzano, E.; Bardwell, H.A.; Pugh, M.; Jones, L.; Russell, R.; Sammut, S.J.; et al. The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes. Nat. Commun. 2016, 7, 11479. [Google Scholar] [CrossRef] [PubMed]
  36. Barroso-Sousa, R.; Jain, E.; Cohen, O.; Kim, D.; Buendia-Buendia, J.; Winer, E.; Lin, N.; Tolaney, S.M.; Wagle, N. Prevalence and mutational determinants of high tumor mutation burden in breast cancer. Ann. Oncol. 2020, 31, 387–394. [Google Scholar] [CrossRef] [PubMed]
  37. McCart Reed, A.E.; Kalinowski, L.; Simpson, P.T.; Lakhani, S.R. Invasive lobular carcinoma of the breast: The increasing importance of this special subtype. Breast Cancer Res. 2021, 23, 6. [Google Scholar] [CrossRef]
  38. Vasaikar, S.V.; Straub, P.; Wang, J.; Zhang, B. LinkedOmics: Analyzing multi-omics data within and across 32 cancer types. Nucleic Acids Res. 2018, 46, D956–D963. [Google Scholar] [CrossRef]
  39. Kanda, Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant. 2013, 48, 452–458. [Google Scholar] [CrossRef] [PubMed]
Ijms 25 08961 g001
Figure 1. Overall survival (OS), progression-free survival (PFS), and relapse-free survival (RFS) in CDH1-altered and -unaltered ILC. (a) No significant difference in OS was observed between CDH1-altered (n = 181) and -unaltered (n = 166) ILC (p = 0.97). (b) No significant difference in PFS was observed between CDH1-altered (n = 110) and -unaltered (n = 91) ILC (p = 0.97). (c) No significant difference in RFS was observed between CDH1-altered (n = 86) and -unaltered (n = 98) ILC (p = 0.57).
Figure 1. Overall survival (OS), progression-free survival (PFS), and relapse-free survival (RFS) in CDH1-altered and -unaltered ILC. (a) No significant difference in OS was observed between CDH1-altered (n = 181) and -unaltered (n = 166) ILC (p = 0.97). (b) No significant difference in PFS was observed between CDH1-altered (n = 110) and -unaltered (n = 91) ILC (p = 0.97). (c) No significant difference in RFS was observed between CDH1-altered (n = 86) and -unaltered (n = 98) ILC (p = 0.57).
Ijms 25 08961 g001
Ijms 25 08961 g002
Figure 2. The genomic landscape of ILC-integrated TCGA and METABRIC datasets. The Oncoprint showing the frequency of genes co-mutated in ILC and copy number alterations. Each column represents a single sample. The frequency of alterations is shown on the left. Multiple genes with altered mutation frequencies, including ILC-related genes, are displayed.
Figure 2. The genomic landscape of ILC-integrated TCGA and METABRIC datasets. The Oncoprint showing the frequency of genes co-mutated in ILC and copy number alterations. Each column represents a single sample. The frequency of alterations is shown on the left. Multiple genes with altered mutation frequencies, including ILC-related genes, are displayed.
Ijms 25 08961 g002
Ijms 25 08961 g003
Figure 3. A comparison of CDH1 mRNA, protein, methylation, and hsa-mir-676 levels between CDH1-mutated and non-mutated ILC. (a) No significant difference in CDH1 mRNA levels was observed between CDH1-altered and -unaltered ILC (p < 0.01, false discovery rate (FDR) = 0.37). The Y-axis represents mRNA expression. RSEM: RNA-Seq by Expectation–Maximization. (b) No significant difference in CDH1 protein levels was observed between CDH1-mutated and non-mutated ILC (p = 0.64, FDR = 0.81). The Y-axis represents reverse-phase protein array (RPPA) expression. (c) No significant difference in CDH1 methylation levels was observed between CDH1-mutated and non-mutated ILC (p = 0.04, FDR = 0.44). The Y-axis represents β values (Val-0.5). (d) No significant difference in hsa-mir-676 levels was observed between CDH1-mutated and non-mutated ILC (p = 0.01, FDR = 0.99). The Y-axis represents expression (RPM, Log2(Val + 1)). RPM: Reads Per Million. The figure shows 0 as CDH1 non-mutated ILC and 1 as CDH1-mutated ILC.
Figure 3. A comparison of CDH1 mRNA, protein, methylation, and hsa-mir-676 levels between CDH1-mutated and non-mutated ILC. (a) No significant difference in CDH1 mRNA levels was observed between CDH1-altered and -unaltered ILC (p < 0.01, false discovery rate (FDR) = 0.37). The Y-axis represents mRNA expression. RSEM: RNA-Seq by Expectation–Maximization. (b) No significant difference in CDH1 protein levels was observed between CDH1-mutated and non-mutated ILC (p = 0.64, FDR = 0.81). The Y-axis represents reverse-phase protein array (RPPA) expression. (c) No significant difference in CDH1 methylation levels was observed between CDH1-mutated and non-mutated ILC (p = 0.04, FDR = 0.44). The Y-axis represents β values (Val-0.5). (d) No significant difference in hsa-mir-676 levels was observed between CDH1-mutated and non-mutated ILC (p = 0.01, FDR = 0.99). The Y-axis represents expression (RPM, Log2(Val + 1)). RPM: Reads Per Million. The figure shows 0 as CDH1 non-mutated ILC and 1 as CDH1-mutated ILC.
Ijms 25 08961 g003
Ijms 25 08961 g004
Figure 4. Gene Ontology (GO) annotation analyses by LinkedOmics using GSEA methods. (A) Bar chart of biological process. Protein localization in endoplasmic reticulum showed significant differences. Despite displaying FDR > 0.05, chaperone-mediated protein complex assembly and protein folding were also recognized as important GO terms. (B) Bar chart of molecular function. tRNA showed significant differences. (C) Bar chart of cellular components. Chaperone complex showed significant differences.
Figure 4. Gene Ontology (GO) annotation analyses by LinkedOmics using GSEA methods. (A) Bar chart of biological process. Protein localization in endoplasmic reticulum showed significant differences. Despite displaying FDR > 0.05, chaperone-mediated protein complex assembly and protein folding were also recognized as important GO terms. (B) Bar chart of molecular function. tRNA showed significant differences. (C) Bar chart of cellular components. Chaperone complex showed significant differences.
Ijms 25 08961 g004
Ijms 25 08961 g005
Figure 5. Flowchart of case selection.
Figure 5. Flowchart of case selection.
Ijms 25 08961 g005
Table 1. Type and frequency of CDH1 alterations.
Table 1. Type and frequency of CDH1 alterations.
Alteration TypeTCGA (n = 110)METABRIC (n = 91)Total (n = 201)
Mutation
 Missense, n (%)4 (3.6)9 (9.9)13 (6.5)
 In-frame, n (%)4 (3.6)1 (1.1)5 (2.5)
 Splice, n (%)11 (10.0)12 (13.2)23 (11.4)
 Truncating, n (%)82 (74.5)65 (71.4)147 (73.1)
Homozygous deletion and mutation, n (%)3 (2.7)1 (1.1)4 (2.0)
Homozygous deletion, n (%)4 (3.6)3 (3.3)7 (3.5)
Structural variant, n (%)2 (1.8)0 (0)2 (1.0)
TCGA, The Cancer Genome Atlas; METABRIC, Molecular Taxonomy of Breast Cancer International Consortium.
Table 2. Comparison of clinicopathological features between CDH1-altered and -unaltered ILC.
Table 2. Comparison of clinicopathological features between CDH1-altered and -unaltered ILC.
Clinicopathological FeatureCDH1-Altered ILC (n = 201)CDH1-Unaltered ILC (n = 192)p-Value
Age
 Mean63.162.10.51
 Minimum3727
 Maximum9071
Site
 Left, n (%)89 (50.0)88 (55.3)0.38
 Right, n (%)89 (50.0)71 (44.7)
 N/A2333
Menopausal status
 Pre, n (%)20 (11.9)30 (19.9)0.07
 Post, n (%)148 (88.1)121 (80.1)
 N/A3341
T factor
 T1, n (%)42 (23.6)39 (25.2)0.99
 T2, n (%)92 (51.7)79 (51.0)
 T3, n (%)43 (24.2)36 (23.2)
 T4, n (%)1 (0.6)1 (0.6)
 N/A2337
N factor
 N0, n (%)58 (53.2)36 (40.0)0.07
 N1, n (%)22 (20.2)33 (36.7)
 N2, n (%)10 (9.2)8 (8.9)
 N3, n (%)19 (17.4)13 (14.4)
 N/A92102
Tumor grade
 Grade 1, n (%)6 (7.1)11 (11.5)0.38
 Grade 2, n (%)54 (63.5)52 (54.2)
 Grade 3, n (%)25 (29.4)33 (34.4)
 N/A11696
TMB
 Mean5.64.20.05
 SD9.544.8
 Median2.62.5
 Minimum00
 Maximum103.128.8
 TMB-low (<10) (%)169 (84.1)159 (88.3)0.29
 TMB-high (≥10) (%)32 (15.9)21 (11.7)
 N/A012
ILC, invasive lobular carcinoma; TMB, tumor mutation burden; SD, standard deviation; N/A, not applicable.
Table 3. Comparison of molecular subtypes between CDH1-altered and -unaltered ILC.
Table 3. Comparison of molecular subtypes between CDH1-altered and -unaltered ILC.
TCGA METABRIC
SubtypeCDH1-Altered (n = 110)CDH1-Unaltered (n = 91)p-ValueCDH1-Altered (n = 91)CDH1-Unaltered
(n = 101)		p-Value
Luminal A, n (%)95 (88.8)39 (70.9)0.0638 (53.5)26 (35.1)<0.05
Luminal B, n (%)4 (3.7)7 (12.7) 14 (19.7)8 (10.8)
Her2, n (%)2 (1.9)1 (1.8) 6 (8.6)8 (10.8)
Basal, n (%)1 (0.9)1 (1.8) 0 (0)4 (5.4)
Normal-like, n (%)5 (4.7)7 (12.7) 11 (15.5)15 (20.3)
Claudin-low, n (%)BlankBlank 2 (2.8)13 (17.6)
N/A336 2027
Her2, Human epidermal growth factor receptor 2; TCGA, The Cancer Genome Atlas; METABRIC, Molecular Taxonomy of Breast Cancer International Consortium; ILC, invasive lobular carcinoma; N/A, not applicable.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Uchida, S.; Sugino, T. Insights into E-Cadherin Impairment in CDH1-Unaltered Invasive Lobular Carcinoma: A Comprehensive Bioinformatic Study. Int. J. Mol. Sci. 2024, 25, 8961. https://doi.org/10.3390/ijms25168961

AMA Style

Uchida S, Sugino T. Insights into E-Cadherin Impairment in CDH1-Unaltered Invasive Lobular Carcinoma: A Comprehensive Bioinformatic Study. International Journal of Molecular Sciences. 2024; 25(16):8961. https://doi.org/10.3390/ijms25168961

Chicago/Turabian Style

Uchida, Shiro, and Takashi Sugino. 2024. "Insights into E-Cadherin Impairment in CDH1-Unaltered Invasive Lobular Carcinoma: A Comprehensive Bioinformatic Study" International Journal of Molecular Sciences 25, no. 16: 8961. https://doi.org/10.3390/ijms25168961

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Article metric data becomes available approximately 24 hours after publication online.
Back to TopTop